All In Biotech

Drug Trial Radar · NCT07387198

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab - A Randomized, Double-blind, Placebo-controlled, Non-comparative Phase II Study

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

135

Planned (sponsor's estimate)

Start

May 29, 2026

Primary completion

Dec 31, 2029

Study completion Jul 31, 2031

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Prof. Gutzmer, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden, Germany; Universität Duisburg-Essen; Regeneron Pharmaceuticals
First posted
Feb 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.

Conditions

  • Merkel Cell Carcinoma, Stage I
  • Merkel Cell Carcinoma, Stage II
  • Neoadjuvant Immunotherapy

Interventions

  • Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cyclesDrug

    Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles

  • Placebo NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.Drug

    Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nodal micrometastases-free rateTime frame: up to 36 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Nationales Centrum für Tumorerkrankungen

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Universitätsklinikum Mannheim

    Mannheim, Baden-Wurttemberg, Germany · Recruiting

  • Universitätsklinikum Tübingen

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • Universitätsklinikum Regensburg

    Regensburg, Bavaria, Germany · Recruiting

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Free and Hanseatic City of Hamburg, Germany · Recruiting

  • Universitätsklinikum Frankfurt

    Frankfurt am Main, Hesse, Germany · Recruiting

  • Klinikum Bielefeld

    Bielefeld, North Rhine-Westphalia, Germany · Recruiting

  • Universitätsklinikum Essen

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • Johannes Wesling Klinikum Minden

    Minden, North Rhine-Westphalia, Germany · Not yet recruiting

  • Universitätsmedizin Mainz

    Mainz, Rhineland-Palatinate, Germany · Recruiting

  • Helios Klinikum Erfurt

    Erfurt, Thuringia, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.